Natural killer (NK)-cell phenotype is partially mediated through binding of killer-cell immunoglobulin-like receptors (KIR) with HLA class I ligands. The KIR gene family is highly polymorphic and not well captured by standard genome-wide association study approaches. Here, we tested the hypothesis that variations in KIR gene content combined with HLA class I ligand status is associated with keratinocyte skin cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). We conducted an interaction analysis of KIR gene content variation and HLA-B (Bw4 vs. Bw6) and HLA-C (C1 vs. C2). KIR centromeric B haplotype was associated with significant risk of multiple BCC tumors (OR, 2.39; 95% confidence interval, 1.10-5.21), and there was a significant interaction between HLA-C and the activating gene KIR2DS3 for BCC (P interaction ¼ 0.005). Furthermore, there was significant interaction between HLA-B and telomeric KIR B haplotype (containing the activating genes KIR3DS1 and KIR2DS1) as well as HLA-B and the activating KIR gene KIR2DS5 (P interaction 0.001 and 0.012, respectively). Similar but greatly attenuated associations were observed for SCC. Moreover, previous in vitro models demonstrated that p53 is required for upregulation of NK ligands, and accordingly, we observed there was a strong association between the KIR B haplotype and p53 alteration in BCC tumors, with a higher likelihood that KIR B carriers harbor abnormal p53 (P < 0.004). Taken together, our data suggest that functional interactions between KIR and HLA modify risks of BCC and SCC and that KIR encoded by the B genes provides selective pressure for altered p53 in BCC tumors. Cancer Res; 76(2); 370-6. Ó2016 AACR.
Introduction
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin are the most commonly diagnosed malignancies in the United States (1) . Although these keratinocyte-derived tumors are treatable and rarely metastasize, they are associated with significant morbidity and considerable healthcare costs (2, 3) . Exposure to UV radiation (UVR) is a major risk factor in the development of these skin cancers and acts as both a mutagen and an immune-suppressing agent (4, 5) . The effect of immunosuppression on skin cancer occurrence is highlighted in organ transplant recipients who are at high risk for the development of SCC and BCC (reviewed in ref. 6 ). In addition, observations of spontaneous BCC regression underscore the importance of the immune response to tumor antigens in tumor progression (7, 8) .
Natural killer (NK) cells are a major component of the innate immune system and serve as the first line of defense against virally infected and transformed cells (9) . NK-cell maturation involves "licensing," a specific set of receptor-ligand interactions between NK receptors and MHC class I molecules (10) . Interindividual variation in these interactions is hypothesized to result in a spectrum of NK killing phenotypes. Once licensed, the cytolytic function of NK cells is orchestrated through a complex array of inhibitory and activating signals, which is in part determined by the interaction of the killer-cell immunoglobulin-like receptors (KIR) with HLA class I ligands, via a balance of inhibitory and activating KIR signals (11) . Expression of cognate HLA class I molecules on target cells results in inhibition of NK-cell-mediated cytolysis via the inhibitory KIR, whereas the absence or aberrant presentation of these molecules leads to activation of the NK cell via activating receptors, including KIR (11) .
The KIR locus is variable in both gene content and allelic polymorphisms (12) (13) (14) . These structural complexities, as well as extensive gene homology, have resulted in poor coverage using GWAS methods, making KIR understudied as a cancer susceptibility trait. The KIR gene region on chromosome 19 is divided into two haplotype blocks, and haplotypes based on gene content have been established (15) . Within each block are the ancestral haplotype A and divergent B haplotypes with increasing diversity primarily of activating KIR genes (15) . Novel KIR structural haplotypes arise from ongoing recombination and unequal crossover events (14, 16) .
Most KIR-ligand pairs have not yet been identified, particularly for the activating KIR (11, 17) . However, HLA-C and HLA-B are both ligands for inhibitory KIR receptors (11) . Furthermore, there is an established dimorphism in both of these genes that results in differential binding of these ligands for KIR receptors, central to the NK licensing process. For example, KIR2DL2 and KIR2DL3 both bind HLA-C1 (defined by Asn80), while KIR2DL1 binds HLA-C2 (Lys80; refs. 12, 18, 19) . Similarly, KIR3DL1 binds specifically to the HLA-Bw4 ligand, but not HLA-Bw6 (defined by sequence at positions 77-83; refs. 12, 19) . Emerging evidence suggests that it is necessary to investigate KIR Ã HLA interactions in order to observe true phenotypes (reviewed in ref. 20) .
Gene content variability at the KIR locus has become central in hematopoietic transplant research (21) and has also been investigated as a susceptibility trait for a variety of infectious and autoimmune diseases, as well as cancer (reviewed in ref. 20) . Moreover, interactions between the independently segregating KIR and HLA genes dictate biologic function of NK cells, yet their interaction in skin cancer susceptibility has only been described for melanoma (22) (23) (24) . Finally, in vitro models demonstrate that functional p53 is necessary for the upregulation of NK ligands (25) . In this study, we tested the hypothesis that variation in KIR gene content and HLA polymorphisms are associated with risk of keratinocyte-derived skin cancers and are a driver of p53 alteration in these common skin cancers.
Patients and Methods

Study population
The New Hampshire Health Study (NHHS) is a populationbased case-control study of keratinocyte cancer and has been previously described (26, 27) . Briefly, a statewide incidence survey was used to identify incident BCC and SCC, and eligible cases were recruited into a case-control study. Cases were (i) 25 to 74 years of age, (ii) had a listed telephone number, and (iii) spoke English. Controls were frequency-matched on age and sex to the combined distribution of cases. Controls ages 25 to 64 years were identified from the New Hampshire State Department of Transportation records and those ages 65 to 74 years were obtained from enrollment lists of the Center for Medicaid and Medicare Services. The participants filled out a work history and residence questionnaire and were administered an interview including demographic factors, pigmentation characteristics, sun exposure and sensitivity, and other factors as previously described (27, 28) . Participants provided a biospecimen of blood or mouthwash rinse for genotyping work. There were 3,247 participants (1,139 controls, 1,235 BCC, and 873 SCC) with available DNA. For this study, we first selected all cases of multiple BCC within 30 days of initial diagnosis (!2 BCC, n ¼ 163, which included 44 subjects !3 BCC), followed by a random selection of single BCC (n ¼ 259), SCC (n ¼ 263), and controls (n ¼ 421).
KIR genotyping
DNA was extracted from buffy coat using Qiagen genomic DNA extraction kits. Multiplex KIR genotyping was performed with a Luminex-based typing kit (Lifecodes Product #545110; Gen-Probe Transplant Diagnostics Inc.). This method captured the presence/absence of 14 KIR genes: 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 2DP1, 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DS1, and 3DL2. The samples were analyzed by the University of Minnesota Cytokine Reference Laboratory on a Bio-Plex instrument.
HLA-C genotyping
The HLA-C alleles can be classified as group C1 ligands, which contain serine (AGC) at codon 77 and asparagine (AAC) at codon 80, and group C2 ligands, which contain asparagine (AAC) at codon 77 and lysine (AAA) at codon 80 (18) . Genotyping of the HLA-C codon 77 polymorphism was performed using an allelic discrimination SNP genotyping assay (Life Technologies) on a LightCycler 480 instrument (Roche). The genotyping was performed according to Roche guidelines, using 10 ng of genomic DNA.
HLA-B genotyping
HLA-B genotyping was performed through two amplification steps, followed by pyrosequencing. The first amplification step (PCR-I) was used to reduce noise, using the method of Pozzi and colleagues (29) . Briefly, 20 ng of purified genomic DNA was used in a 25-mL PCR amplification containing 2.5 mL of 10Â buffer, 5 mL Q-solution (Qiagen), 0.5 mL of 10 mmol/L dNTPs, 0.5 mL of 10 mmol/L HLA-B forward primer (BÂ1), 0.5 mL of 10 mmol/L HLA-B reverse primer (BINT3), and 0.2 mL HotStarTaq DNA polymerase (Qiagen). PCR conditions were as follows: 1 cycle at 94 C for 10 minutes, followed by 8 cycles at 94 C for 20 seconds, 65 C for 30 seconds, 72 C for 2 minutes, followed by 32 cycles at 94 C for 20 seconds, 60 C for 30 seconds, 72 C for 2 minutes, followed by 72 C for 7 minutes, and 4 C hold. This HLA-B-specific PCR-I product was then used for a second amplification step, as described by Yun and colleagues (19) . PCR-II reagents were as follows: 1 mL of PCR-I product, 2.5 mL 10Â buffer, 0.5 mL of 10 mmol/L dNTPs, 0.5 mL of 10 mmol/L HLA-B-forward, 0.5 mL of 10 mmol/L HLA-B-reverse (biotinylated), and 0.2 mL HotStarTaq DNA polymerase (Qiagen), in a 25-mL amplification. PCR-II cycling conditions were as follows: 95 C for 10 minutes, followed by 40 cycles at 94 C for 30 seconds, 57 C for 30 seconds, 72 C for 1 minute, followed by 72 C by 10 minutes, and 4 C Hold. Twenty microliters of PCR-II product were used for pyrosequencing. Sequencing was carried out using a Pyromark Q96 MD (Qiagen) pyrosequencing apparatus and HLA-B sequencing primer 
KIR haplotype determination
KIR haplotypes were assigned based on gene content and known linkage disequilibrium, as described by Pyo and colleagues (16) . The KIR 2DL5-2DS3/2DS5 genic block was not used for haplotype assignment due to ambiguity of location. The KIR region was considered as two independent haplotype blocks (centromeric and telomeric). Within each haplotype block, an individual was assigned as A/A, A/B, or B/B, reflecting haplotypes inherited from each parent. The centromeric haplotypes were defined as follows: A/A (containing both 2DL3 and 2DP1/2DL1, with no D2L2 or 2DS2 present), A/B (containing 2DL3, 2DL2, and 2DS2), and B/B (containing both 2DS2 and 2DL2 with no 2DL3 present). Telomeric haplotypes were defined as: A/A (containing 3DL1 and 2DS4, with no 3DS1 or 2DS1 present), A/B (containing 3DL1, 2DS4, 2DS1, and 3DS1), and B/B (containing 2DS1 and 3DS1, with no 3DL1 or 2DS4 present). Using this definition of KIR, individuals have 4 KIR haplotypes; this definition reflects the haplotype block structure (2 blocks, 1 centromeric and 1 telomeric) and the inheritance of a haplotype from each parent for each block. Missing KIR data were imputed using the established linkage disequilibrium among genes to categorize the participants into these most common KIR haplotypes. For 16 samples, telomeric haplotype could not be determined due to 2DS4 control probe failure. Eighty-three (7.5%) samples (23 controls, 35 SCC, and 25 BCC) were excluded due to poor DNA sample quality.
P53
We requested the original paraffin-embedded tumor specimens for histopathology re-review. The study dermatopathologist performed a standard histopathology re-review that included classification of tumor morphology, grade, associated actinic keratoses, degree of histologic solar elastosis, and the percentage of tumor present in the tissue specimen. In a subset of tumors, immunohistochemical (IHC) analysis of p53 was performed using standard approaches (30) and were scored on two scales: the percent of tumor cells staining positively (negative, trace, 0-100%) and staining intensity (1, 2, 3þ). Tumors with a 3þ intensity score in 10% or more of tumorous cells were considered p53 IHC positive (as described in ref. 31) . TP53 mutation for this study was previously described in Almquist and colleagues (32) . IHC and mutation data were combined into a single metric to indicate abnormal p53 status and were available for 100 BCC and 100 SCC tumors.
Statistical analysis
We used unconditional logistic regression to compute ORs and 95% confidence intervals (95% CI) for BCC and SCC. All models were adjusted for age at diagnosis (continuous), sex, and skin type. Skin type was defined as the reaction to 1 hour of sun exposure the first time in the summer; those who responded that they had a severe sunburn with blistering, or painful sunburn for a few days followed by peeling, were classified as skin type "Burn," and those who responded that they tanned without any sunburn, or had a mild burn followed by tanning, were classified as "Tan." We conducted interaction testing for KIR Ã HLA and skin cancer risk using the likelihood ratio test comparing logistic regression models with and without the interaction term. Separate analyses were performed for SCC and BCC. Statistical analyses were performed in R v2.13.1 using the EpiCalc package.
Results
We conducted genotype analyses of KIR and HLA-C and B dimorphisms in 1,023 participants (398 controls, 387 BCC, and 238 SCC). The demographic characteristics of study subjects are presented in Table 1 . To investigate the association of KIR gene content and keratinocyte cancer risk, we conducted haplotypelevel analysis of the independently inherited centromeric and telomeric haplotype blocks of the KIR locus ( Table 2) . No overall associations were found for SCC or BCC in haplotype-level analysis (Table 2 ). Of the 387 BCC, there were 44 subjects with !3 tumors removed within 30 days of diagnosis. Centromeric B/B haplotypes were associated with significant elevation in risk of multiple (!3) BCC (OR, 2.39; 95% CI, 1.10-5.21; Table 2 ). We similarly investigated the single gene effects of HLA-C and HLA-B dimorphism (Table 3) . Although no differences in risk of keratinocyte cancer were found with HLA-C genotype, the HLA-Bw4 homozygous genotype was associated with a significant reduction in risk of SCC (OR, 0.58; 95% CI, 0.34-0.99; Table 3 ).
The biologic interaction between HLA class I ligand and inhibitory KIR determines NK-cell licensing and subsequent potential to respond to activating signals. We therefore conducted an interaction analysis of KIR gene content variation and HLA-C (Table 4) and HLA-B (Table 5 ). There was a statistically significant interaction between HLA-C and KIR2DS3 for both BCC (P < 0.005) and SCC (P ¼ 0.038), with those having both HLA-C1/ C1 and the KIR2DS3 genes demonstrating elevated risk of both types of keratinocyte caner (Table 4 ). In addition, for BCC, there were statistically significant interactions between HLA-B and telomeric B haplotypes (containing KIR2DS1 and KIR3DS1, P < 0.001) as well as HLA-B and KIR2DS5 (P ¼ 0.012; Table 5 ). For both interactions, those with the Bw4/Bw4 genotype and the activating KIR gene had reduced risk of BCC, where the effect was attenuated, or possibly reversed, among those carrying a Bw6 allele. Similar nonsignificant trends were observed for SCC.
Finally, we tested the hypothesis that KIR B haplotype blocks were associated with alteration at p53 (defined as either mutation or altered IHC; Fig. 1 ). Among 100 BCC tumors, there was a strong 
Discussion
Using a population-based case-control study of BCC and SCC, we tested the hypothesis that KIR gene content and HLA class I dimorphisms play a role in the development of keratinocyte cancer and result in selective pressure for p53 alteration. There was limited evidence for single gene effects. Not unexpectedly, because these gene products physically interact to alter NK-cell phenotype, it was necessary to look at interactions between the genes to reveal disease associations. In particular, the presence of the activating KIR2DS3 gene with HLA-C1 was associated with an approximate doubling of risk for BCC and SCC. In contrast, telomeric B (containing KIR2DS1 and KIR3DS1) and 2DS5 were inversely associated with BCC among HLA-Bw4/Bw4 carriers. These findings suggest a complex interplay of KIR/HLA in the etiology of keratinocyte-derived cancers.
To date, there has been limited investigation of NK-cell genetics and somatic mutations. One might expect that genetic variation in immune surveillance influences what somatic mutations go "unseen" and can develop into tumors. In vitro work has demonstrated that p53 is necessary for the upregulation of stress ligands that would activate NK receptors (25) . Extending this model to human populations would suggest that p53 must be inactivated among those with a robust NK response (those with B haplotypes). Our data are very consistent with this hypothesis.
Previous studies have investigated whether individual KIR genes act as risk traits for solid tumors. In breast and lung cancers, genes contained in B haplotypes (KIR 2DS1, 3DS1, and 2DS5) were associated with increased cancer risk (33) . Also, increased numbers of activating KIR genes were associated with nasopharyngeal carcinoma (34) . These studies suggest that an environment of active NK cells may contribute to carcinogenesis. Similarly, our finding that centromeric B/B haplotypes are associated with over 2-fold risk of multiple BCC (!3) may also result from inappropriate or chronic activation of NK cells. In contrast with these studies, melanoma risk and progression were associated with inhibitory KIR and inhibitory KIR/HLA combinations (22) (23) (24) .
Our approach focused on the joint effect of KIR and their licensing partners HLA-C and B. Increased BCC and SCC risk with KIR2DS3 in those homozygous for HLA-C1 was unexpected, as there is no reported biologic interaction between KIR2DS3 and HLA-C, and KIR2DS3 has low cell-surface expression (35) . Hierarchy of affinity in inhibitory KIR/HLA interactions has been suggested to play an important role in tuning NK-cell response (9, 20) . The presence of the activating KIR may further attenuate this process and enhance NK-cell activation (36). Thus, it is possible that when interacting with homozygous C1 ligands, NK cells have a lower activation threshold in the presence of activating KIR2DS3, resulting in NK-cell hyperactivity. Although such a response may be protective in infection control (37) , it may be deleterious for cancer development, as increased NK-cell activation may result in prolonged inflammation and tissue destruction. Another explanation for our observed interaction between HLA-C and KIR2DS3 is rooted in the known genetic linkage of this region. KIR2DS3 occurs on B haplotypes (both centromeric and telomeric) and is therefore in partial linkage with centromeric genes known to interact with HLA-C. As the field progresses to more sophisticated KIR typing methods, it will be possible to refine our definitions of haplotypes and directly address this question.
In contrast with our observations of increased risk associated with centromeric activating KIR, reduced risk was observed with activating genes (KIR2DS1, KIR3DS1, and 2DS5) among HLABw4 homozygous individuals. This pattern of risk reduction is consistent with expected enhancement of NK-cell effector function, in the presence of activating receptors, when NK cells have been licensed through Bw4 (20, 38) . Only Bw4, but not Bw6, epitopes bind to the inhibitory telomeric KIR3DL1 (which was present in >95% of our study population) and participate in licensing of NK cells (12) . These results may be particularly robust for BCC, as these tumors have low or absent HLA class 1 expression (39-41), making them particularly susceptible to NK killing. HLA-Bw4 has been associated with increased NK-cell responsiveness to tumor stimulation in vitro. NK cells from individuals with 3DL1þ/Bw4/4, compared with 3DL1þ/Bw4/6 or Bw6/6, reported greater response to tumor cells and increased IFNg production (42) . The presence of activating KIR has also been shown to enhance IFNg secretion in cell culture (43) . In addition, the presence of KIR3DS1 was associated with increased IFNg levels and greater NK-cell activity in early HIV-I infection (44) . Our results suggest that Bw4 licensing combined with activating signals may be important in immune editing for BCC and SCC. IFNg is important in antitumor responses (45) and skin cancer surveillance (46) (47) (48) . More efficient NK-cell activation with increased IFNg production may contribute to the reduced risk in skin cancers associated with the activating telomeric KIR and HLABw4 genotype.
Although the KIR literature primarily focuses on NK cells as they are the predominant KIR-expressing cells, subsets of T cells also express KIR, including gd T cells that are more abundant in the skin than NK cells (49, 50) . The gd T cells can respond to stress signals via T-cell receptor-adaptive and innate mechanisms, including the activating receptor NKG2D. Furthermore, gd T cells can enhance innate immunity through upregulation of T helper 1 cytokines, including IFNg, to stimulate NK-cell responses (50) . Experiments in mice revealed that gd T cells are able to inhibit early carcinogenesis and the progression of SCC and melanoma (50) . Thus, the effects observed in this study may not only be a result of NK-cell functionality, but may also reflect activity of the gd T cells. Further research is needed to understand the role of KIR in gd T cells and whether they also undergo licensing through KIR-HLA interactions.
This study had several limitations, including multiplexed KIR genotyping that was prone to allelic dropout. To address this problem, we used published linkage disequilibrium information to impute missing data for KIR genes. Analyses restricted to those subjects without imputation did not change the study results. The KIR 2DL5-2DS3/2DS5 genic block could not be unambiguously assigned to centromeric and/or telomeric segments due to the limits of the genotyping methodology. Our HLA-Bw4 typing method was specific to HLA-B; there are a few HLA-A alleles that carry Bw4 epitopes (HLA-A23, 24, 25, and 32), which would be misclassified using our method (12) . Approximately 7.5% of our study population was excluded from statistical analysis due to insufficient DNA sample quality for complex genotyping. Other limitations included lack of replication in an independent population and multiple statistical comparisons. In addition, we were underpowered to detect differences in risk based on Bw4 position 80 (isoleucine vs. threonine), which affects KIR3DL1 binding (38) , to test further gene Ã gene interactions or conduct refined analyses of the multiple BCC phenotype, an important clinical problem that may have an underlying genetic component.
In conclusion, our findings suggest differential BCC and SCC risk with centromeric and telomeric activating KIR, and selective pressure from this interindividual variability drives p53 alteration in skin tumors. Our study underscores the importance of investigating KIR in combination with HLA as has been done for bone marrow transplant and melanoma (21) (22) (23) (24) . Future research should include high-resolution typing of KIR and HLA and further investigate the multiple BCC phenotype.
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